Trials / Terminated
TerminatedNCT03038971
Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
A Single-Center, Double-Blinded, Placebo-Controlled, Phase 1 Evaluation of the Safety of Ragweed Mix Given in Four Monthly Doses by Intralymphatic Node Injections for Inducing Tolerance in Subjects With Ragweed Induced Allergic Conjunctivitis and Allergic Rhinitis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Woodmont Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A safety study conducted on subjects ≥16 years old evaluating the safety of 4 intralymphatic injections of 2 different dose levels of the investigational short and tall ragweed product. Biomarkers will be assessed at baseline and at multiple time points post-treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dose Level 1 | Short and Tall Ragweed Mix |
| BIOLOGICAL | Dose Level 2 | Short and Tall Ragweed Mix |
| BIOLOGICAL | Placebo | Saline with 0.4% Phenol |
Timeline
- Start date
- 2017-03-30
- Primary completion
- 2017-04-29
- Completion
- 2017-04-29
- First posted
- 2017-02-01
- Last updated
- 2018-02-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03038971. Inclusion in this directory is not an endorsement.